CD40
癌症免疫疗法
免疫系统
材料科学
免疫疗法
抗体
树突状细胞
癌症研究
癌症
细胞生物学
生物
免疫学
医学
细胞毒性T细胞
生物化学
内科学
体外
作者
Muhetaerjiang Mamuti,Yi Wang,Yong- Dan Zhao,Jiaqi Wang,Jie Wang,Yan‐Lei Fan,Wuyi Xiao,Da‐Yong Hou,Jia Yang,Rui Zheng,Huimin An,Hao Wang
标识
DOI:10.1002/adma.202109432
摘要
Targeted immunomodulation through biomolecule-based nanostructures, especially to dendritic cells (DCs), holds great promise for effective cancer therapy. However, construction of high-performance agonist by mimicking natural ligand to activate immune cell signaling is a great challenge so far. Here, a peptide-based nanoagonist toward CD40 (PVA-CD40) with preorganized interfacial topological structure that activates lymph node DCs efficiently and persistently, achieving amplified immune therapeutic efficacy is described. The on-site fabrication of PVA-CD40 is realized through the click conjugation of two functional peptides including the "CD40 anchoring arm" and the "assembly-driving motor." The resultant polyvalent interface rapidly triggers the receptor oligomerization and downstream signaling. Strikingly, one shot administration of PVA-CD40 elicits maturation period of DCs up to 2.3-fold comparing to that of CD40 antibody. Finally, combining the PVA-CD40 with anti-PD-1 antibody results in subsequent inhibition of tumor growth in both B16F10 and 4T1 mice tumor models with survival rate up to 37%, while none of the mice survives in the clinically relevant CD40 mAb and anti-PD-1 combination-treated group. It is envisioned that the fabrication of antibody-like superstructures in vivo provides an efficient platform for modulating the duration of immune response to achieve optimal therapeutic efficacy.
科研通智能强力驱动
Strongly Powered by AbleSci AI